The Amyloidosis Channel is supported with funding from Prothena (Silver).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
COMy 2021 | Redefining the standard of care in AL amyloidosis
Artur Jurczyszyn, MD, PhD, Jagiellonian University Medical College, Kraków, Poland, discusses recent data in the AL amyloidosis space that has the potential to change the standard of care. The Phase III ANDROMEDA study (NCT03201965) evaluated daratumumab in combination with cyclophosphamide, bortezomib, and dexamethasone (CyBorD), compared to CyBorD. Significant benefit was elicited with the additional use of daratumumab, leading to daratumumab becoming the first drug to be approved for the treatment of AL amyloidosis. The daratumumab plus CyBorD combination is emerging as a new standard of care. This interview took place during the 7th World Congress on Controversies in Multiple Myeloma (COMy), 2021.
